New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
De Novo Antibody Sequencing Case Study
Abterra Bio uses bioinformatics and mass spectrometry to reconstructs the full amino acid sequence of both antibody chains. We’ve successfully sequenced human, mouse, rat, hamster, rabbit, and llama antibodies. This approach can be applied across any species and...
A Decade of De Novo Antibody Sequencing Experience
De novo antibody sequencing experience Have you lost your hybridoma? Is your hybridoma no longer producing? Is your hybridoma producing more than your desired antibody? Do you have a monoclonal antibody from a clinical sample, but no way to recover the source B cell?...
New Publication Reveals Ebolavirus-Neutralizing Monoclonal Antibodies
Abterra Biosciences, together with VUMC Vaccine Center, Mapp Bio, PNNL, UTMB Health, Ragon Institute, Integral Molecular, and La Jolla Institute, recently published a paper describing the discovery of Ebolavirus-neutralizing antibodies from convalescent plasma.Read...
Get In Touch